

# Index

## A

- Abdominal wall closure, temporary and permanent method, 258–261
- Acute arterial thrombosis, 205
- Acute mesenteric ischemia (AMI)
  - clinical presentation, 201
  - contemporary results, 271, 272
  - diagnostic considerations and imaging studies, 201–203
  - duplex ultrasound, 59
  - endovascular revascularization (*see* Endovascular revascularization, AMI)
  - epidemiology
    - incidence, 36–37
    - nonocclusive mesenteric ischemia, 39
    - thromboembolic, 37–39
  - etiology, 200–201
  - history, 199–200
  - long-term survival, 273–274
  - magnetic resonance angiography, 85–87
  - management by etiology
    - acute arterial thrombosis, 205
    - arterial embolism, 204–205
    - mesenteric venous thrombosis, 206–208
    - nonocclusive mesenteric ischemia, 205–206
  - mortality rate, 199, 265
  - natural history, 39–40
  - newer technique results, 273
  - open and hybrid mesenteric revascularization
    - complications, 237
    - considerations, 226–237
    - diagnosis, 225–226
    - initial treatment and resuscitation, 226
    - outcomes, 237
    - postoperative care, 237
    - outcomes, 268–269
    - treatment, 268–269
    - US Nationwide Inpatient Sample, 266–268
- Acute mesenteric vein thrombosis
  - clinical presentation, 300–301
  - diagnosis, 302–303
    - computed tomography, 304
    - cross-sectional imaging, 304–305
    - laboratory investigation, 303
    - MRI, 304
  - treatment
    - clinical experience, 327
    - endovascular techniques, 329
    - management algorithm, 330
    - portal vein, 328
    - superior mesenteric vein, 326
    - systemic anticoagulation, 328–329
- Acute pancreatitis, 313
- American Gastroenterological Association guideline, 339
- AMI. *See* Acute mesenteric ischemia (AMI)
- Aneurysmectomy, 443
- Aneurysms, mesenteric
  - epidemiology, 43–44
  - natural history, 44–45
- Angiography
  - CMI, diagnostic considerations, 111
  - NOMI, 339
- Antegastric approach, 368–369
- Anticoagulant therapy, 320
- Antidiarrheal medications
  - diphenoxylate-atropine, 285–286
  - loperamide, 285
  - opioids, 286

- Antiplatelet therapy, 424
- Antisecretory medications  
  clonidine, 287  
  octreotide, 286–287
- Arc of Riolan, 19
- Arterial embolism, 204–205, 211, 212
- Arteriovenous fistulae, 432
- B**
- Behçet syndrome (BS), 134–135
- Bowel resection, 269, 270
- Buerger's disease. *See* Thromboangiitis obliterans (TAO)
- C**
- CAAs. *See* Celiac artery aneurysms (CAAs)
- Catheter-directed thrombolytic therapy, 411
- Celiac artery anastomosis, 152
- Celiac artery aneurysms (CAAs)  
  clinical presentation, 434  
  epidemiology and etiology, 437  
  issues, 450  
  rupture rate, 439
- Celiac artery compression, 349
- Celiac artery dissection (CAD)  
  clinical presentations, 389–390  
  etiology, 392  
  high-grade stenosis, 393  
  open repair, 410  
  open surgical repair, 408, 409  
  splenic artery, 393, 394
- Celiac ganglion injection, 353–354
- Celiac stenosis, 350–351
- Centers for Medicare and Medicaid Services (CMMS), 288
- Cholecystokinin (CCK), 28, 278
- Chronic mesenteric ischemia (CMI)  
  clinical presentation, 105–107  
  diagnostic angiography, 97  
  diagnostic considerations, 110, 118–119  
  angiography, 111  
  computed tomographic angiography, 113–116  
  duplex ultrasonography, 111–113  
  magnetic resonance angiography, 116–118  
  tonometry, 118  
  endovascular revascularization (*see* Endovascular revascularization, CMI)  
  epidemiology, 33–35  
  etiology, 107–110  
  functional testing, diagnosis  
    biomarkers, 73  
    gastric tonometry, 64–67  
    risk stratification, single-nucleotide polymorphisms, 74  
    small bowel mucosa, 73  
    visible light spectroscopy, 67–69  
  indication, 25  
  magnetic resonance angiography, 82–85  
  natural history, 35–36  
  non-atherosclerotic causes  
    (*see* Non-atherosclerotic causes, mesenteric arterial disease)  
  pathophysiology, 30
- Chronic mesenteric vein thrombosis  
  algorithm for management, 332  
  clinical presentation, 301, 302  
  diagnosis, 306  
  treatment  
    management, 331–332  
    progression CT, 331, 332
- Clonidine, 287
- Coaxial system, 447
- Coil embolization  
  endovascular therapy, 452, 453  
  gastrooduodenal branch  
    aneurysm by, 444, 450  
  ruptured intrahepatic aneurysm, 452
- Collateral pathways, 16–19, 29
- Computed tomography (CT)  
  acute MVT, 304  
  chronic MVT, 306  
  MDCT, 80  
  NOMI, 340  
  progression, splenic vein thrombosis, 331, 332  
  rationale, 79–80  
  subacute MVT, 305
- Computed tomography angiography (CTA), 340  
  celiac stenosis, 351  
  clinical role and imaging considerations, 80–81  
  CMI, diagnostic considerations, 113–116  
  IVAD, 394–398  
  limitations, 90–91  
  SMAD, 395–398  
  thoracic thrombus, 100  
  VAA, 440, 441
- Contrast arteriography, 398–399
- Contrast-enhanced magnetic resonance angiography (CE-MRA), 340
- Cross-sectional imaging, acute MVT, 304–305

**D**

- Diagnostic angiography
  - catheters
    - frequently utilized guide, renal and mesenteric interventions, 99
    - and injection rates, 98
    - shapes, 99
  - chronic mesenteric ischemia, 97
  - femoral/brachial approach, 96
  - lateral aortography, 97
  - percutaneous femoral access, 96
  - selective injection, mesenteric arteries, 96–97
  - selective visceral artery angiography, 96, 98
- Dietary strategy
  - food items and drinks, 282
  - requirements and recommendations, 282
- Digital subtraction angiography (DSA), 339
- Diphenoxylate-atropine, 285–286
- Double-coaxial technique, 412
- Duplex ultrasonography (DUS)
  - CMI, diagnostic considerations, 111–113
  - IVAD, diagnosis, 393–394
  - mesenteric vessels
    - acute mesenteric ischemia, 59
    - inflammatory bowel disease, 40
    - intraoperative imaging, 55–56
    - median arcuate ligament syndrome, 59
    - mesenteric artery dissection and aneurysms, 60
    - normal waveforms, 52
    - post-intervention imaging, 57–58
    - stenosis detection, 53–55
    - technique, 49–52
  - VAA, 440

**E**

- Embolectomy
  - celiac artery, 218–220
  - incidence, 267
  - inferior mesenteric artery, 220
  - open mesenteric catheter (*see* Mesenteric embolism)
  - superior mesenteric artery, 217–218
- Embolization, 411, 449
- End-jejunostomy, 278, 279
- Endovascular intervention, SIVAD, 422, 424–426
- Endovascular revascularization
  - AMI
    - history, 241
    - results, 250–251
    - treatment options, 242–250

**CMI**

- access site selection, 169
- angioplasty and stenting, mesenteric stenosis, 173–175
- bifurcated stents, 179
- complications, 183
- contemporary results, 191–193
- diagnostic mesenteric angiography, 169–170
- early results, 188–189
- embolic protection devices, 171–172
- history, 187–188
- indications, 166–175
- in-stent stenosis, 181–182
- mesenteric intervention vs. open surgery, 189–191
- mesenteric occlusions
  - recanalization, 175–177
  - open revascularization vs., 166–168
  - orbital atherectomy, 177–179
  - post-procedure management, 183
  - pre-procedure evaluation, 168–169
  - retrograde hybrid
    - revascularization, 179–181
    - selective catheterization, 170–171
    - stent choice, 172–173
- isolated visceral artery dissection
  - catheter-directed thrombolytic therapy, 411
  - embolization, 411
  - stenting visceral arteries, 412–413
- visceral artery aneurysms, 443–446, 452–453
  - open surgical techniques vs., 453–454

**F**

- FDSs. *See* Flow-diverting stents (FDSs)
- Fibrotic celiac ganglion compression, 349
- Flow-diverting stents (FDSs), 445–446
- Functional testing, chronic mesenteric ischemia
  - biomarkers, 73
  - gastric tonometry, 64–67
  - risk stratification, single-nucleotide polymorphisms, 74
  - small bowel mucosa, 73
  - visible light spectroscopy, 67–69

**G**

- GAAs. *See* Gastric artery aneurysms (GAAs)
- Ganglion resection, MALS, 359

- Gastric artery aneurysms (GAAs)  
 clinical presentation, 434  
 epidemiology and etiology, 438  
 issues, 450
- Gastric exercise tonometry (GET), 65
- Gastric tonometry  
 after intervention, 67  
 diagnostic value, 67  
 injection, MALS, 353–354  
 intraluminal PCO<sub>2</sub> measurement, 64  
 ischemia detection, 64–65  
 limitations, 70  
 optimization, 72  
 procedure  
   gastric exercise tonometry, 65  
   24-hour tonometry, 65–66  
   test meals, 66  
 sensitivity and specificity, 67  
 vs. VLS, 69–70
- Gastrocolic ligament approach. *See*  
 Retrogastric approach
- Gastroduodenal artery aneurysms (GDAAs)  
 clinical presentation, 434–435  
 epidemiology and etiology, 438  
 issues, 450  
 rupture rate, 439
- Gastroepiploic artery aneurysms (GEAAs)  
 clinical presentation, 434–435  
 epidemiology and etiology, 438  
 issues, 450  
 rupture rate, 439
- Gastrohepatic ligament approach. *See*  
 Antegastric approach
- Gastrointestinal (GI) involvement, vasculitis  
 anatomic considerations, 124  
 angiography, 130  
 clinical features, 125–128  
 computed tomography, 129–130  
 duplex ultrasound, 129  
 endoscopy and colonoscopy, 129
- GDAAs. *See* Gastroduodenal artery aneurysms  
 (GDAAs)
- GEAAs. *See* Gastroepiploic artery aneurysms  
 (GEAAs)
- Giant cell arteritis (GCA), 110, 131
- Glutamine, 287
- Growth hormone (GH), 287
- H**
- HAAs. *See* Hepatic artery aneurysms (HAAs)
- Henoch–Schönlein syndrome (HSS), 133
- Hepatic artery aneurysms (HAAs)  
 clinical presentation, 433  
 epidemiology and etiology, 437  
 issues, 448–449  
 rupture rate, 439
- Hepatic artery dissection (HAD)  
 clinical presentations, 390  
 etiology, 392  
 indications, 407  
 open repair, 410
- Home parenteral nutrition (HPN), 283, 284
- Hybrid mesenteric revascularization, 273
- I**
- IMA. *See* Inferior mesenteric artery (IMA)
- IMAAs. *See* Inferior mesenteric artery  
 aneurysms (IMAAs)
- Inferior mesenteric artery (IMA), 431  
 anatomy  
   normal, 15–16  
   variant, 22  
   vascular, 26
- Inferior mesenteric artery aneurysms (IMAAs)  
 clinical presentation, 435  
 epidemiology and etiology, 438–439  
 issues, 451
- Inflammatory bowel disease, 60
- In-stent stenosis, 181–182
- Intravascular ultrasound, 101
- Isolated hepatic artery dissections. *See* Hepatic  
 artery dissection (HAD)
- Isolated mesenteric artery dissection (IMAD)  
 epidemiology, 42–43  
 natural history, 43
- Isolated visceral artery dissection (IVAD)  
 clinical presentations  
   CAD, 389–390  
   RAD, 390–391  
   SMAD, 388–389  
 conservative management, 407–408  
 diagnosis  
   CTA, 394–398  
   DUS, 393–394  
   laboratory studies, 399–400  
   MRA, 398  
   selective contrast arteriography, 398–399  
 endovascular revascularization  
   (*see* Endovascular revascularization)  
 epidemiology, 388  
 etiology  
   HAD, 391–392  
   RAD, 391–392  
   SMAD, 391–392

- indications, 407
  - open surgical revascularizations  
(*see* Open surgical techniques)
  - pathology, 387–388
- J**
- Jejunocolic anastomosis, 278, 279
  - Jejunioileal anastomosis, 278, 279
- L**
- Laparoscopic division, clinical outcomes, 377–379
  - Laparoscopic transperitoneal approach
    - flexible-tip, 371
    - L-shaped hook monopolar cautery, 371–372
  - for MALS
    - minimally invasive approach, 363–364
    - patient positioning, 363–364
    - surgery, 363–364
  - Nathanson liver retractor, 372
  - oblique-viewing, 370
  - Robot-assisted technique, 369–370
  - surgical approaches
    - antegastric approach, 368–369
    - left crus approach, 366–367
    - retrogastric approach, 364–365
    - right crus approach, 365–366
    - vessel approach, 367–368
  - surgical technique, 362
  - trocars, 371
  - ultrasonic dissector, 371
  - Laparotomy, 345, 412
    - vs.* open and endovascular revascularization, rates, 269, 270
  - Lateral aortography, 97
  - Left crus approach, 366–367
  - Leiden Thrombophilia Study, 315
  - Liver function tests, 399–400
  - Loperamide, 285
  - L-shaped hook monopolar cautery, 371–372
- M**
- Magnetic resonance angiography (MRA)
    - acute mesenteric ischemia, 85–87
    - chronic mesenteric ischemia, 82–85
    - clinical role and imaging considerations, 81–82
    - CMI, diagnostic considerations, 116–118
    - diagnosis, 398
    - limitations, 91
    - MALS, 353
    - median arcuate ligament syndrome, 89
    - mesenteric artery
      - dissection/aneurysm, 89–90
    - mesenteric venous thrombosis, 87–88
    - nonocclusive mesenteric ischemia, 88
    - rationale, 79–80
    - VAA, 440
  - Magnetic resonance imaging (MRI)
    - acute MVT, 304
    - chronic MVT, 306
    - IVAD, 398
    - NOMI, 340
    - subacute MVT, 305
  - Mechanical thrombectomy/thrombolysis, 269
  - Median arcuate ligament syndrome (MALS)
    - celiac ganglion and gastric tonometry injection, 353–354
    - clinical outcomes
      - laparoscopic division, 377–379
      - open division, 379–382
    - clinical presentation, 376–377
    - differential diagnosis, –354
    - duplex ultrasound, 59
    - endovascular treatment role, 359–360
    - epidemiology, 39–42
    - etiology, 349
    - ganglion resection, 359
    - history and physical, 350
    - imaging
      - celiac and SMA, 351
      - cholecystectomy, 351, 352
      - CTA, 351
      - MRA, 353
    - intraoperative ultrasound, 358, 359
    - magnetic resonance angiography, 89
    - nasogastric tube, 357–358
    - natural history, 42
    - neurogenic compression, 376
    - pathophysiology, 375
    - postoperative care, 360
    - radiographic evaluation, 376–377
    - subcostal incision, 357
    - surgical treatment, 376
    - symptoms, 357
  - Mesenteric artery dissection/aneurysm
    - epidemiology, 43–44
    - duplex ultrasound, 60
    - magnetic resonance angiography, 89–90
    - natural history, 44–45

- Mesenteric embolism
- diagnosis
    - patient population, 213
    - preoperative imaging, 213–215
    - preoperative testing, 213
  - preoperative considerations, 215–216
  - second look laparotomy role, 220–221
  - surgical outcomes, 222
  - surgical treatment
    - celiac artery embolectomy, 218–220
    - inferior mesenteric artery
      - embolectomy, 220
    - small bowel evaluation, abdominal
      - exploration, 216–217
    - superior mesenteric artery
      - embolectomy, 217–218
- Mesenteric ischemia, non-atherosclerotic causes
- differential diagnosis, 135–138
  - gastrointestinal (GI) involvement, vasculitis
    - anatomic considerations, 124
    - angiography, 130
    - clinical features, 125–128
    - computed tomography, 129–130
    - duplex ultrasound, 129
    - endoscopy and colonoscopy, 129
  - mesenteric vasculitis, specific disorders
    - Behçet syndrome, 134–135
    - Giant cell arteritis, 131
    - Henoch–Schönlein syndrome, 133
    - microscopic polyangiitis, 133
    - polyarteritis nodosa, 131–132
    - rheumatoid vasculitis, 134
    - systemic lupus erythematosus, 134
    - Takayasu’s arteritis, 131
    - thromboangiitis obliterans, 135
    - Wegener granulomatosis, 133
  - neurofibromatosis, 140–143
  - treatment, 138–140
- Mesenteric occlusions recanalization, 175–177
- Mesenteric revascularization. *See*
- Endovascular revascularization;
  - Open mesenteric reconstructions
- Mesenteric vascular disease history
- endovascular therapy, 5–6
  - Mayo Clinic legacy, 5
  - surgical revascularization, 4
- Mesenteric vascular supply
- duplex ultrasound (*See* Duplex ultrasonography (DUS))
  - embryology, 9–10
  - normal anatomy
    - celiac artery, 10–13
    - collateral pathways, 16–19
    - inferior mesenteric artery, 15–16
    - superior mesenteric artery, 14–15
  - variant anatomy
    - celiac artery variants, 19–21
    - IMA variants, 22
    - SMA variants, 21–22
  - vascular anatomy, 26
  - physiologic response, 27–29
- Mesenteric vasculitis, non-atherosclerotic causes
- Behçet syndrome, 134–135
  - giant cell arteritis, 131
  - Henoch–Schönlein syndrome, 133
  - microscopic polyangiitis, 133
  - polyarteritis nodosa, 131–132
  - rheumatoid vasculitis, 134
  - systemic lupus erythematosus, 134
  - Takayasu’s arteritis, 131
  - thromboangiitis obliterans, 135
  - Wegener granulomatosis, 133
- Mesenteric vein thrombosis (MVT), 295–296
- acute (*see* Acute mesenteric vein thrombosis)
  - AMI management by etiology, 206–208
  - chronic (*see* Chronic mesenteric vein thrombosis)
  - clinical presentation, 300–302
  - diagnosis, 302–306
  - etiopathogenesis, 297–299, 327
    - extraluminal effects, 299
    - intraluminal causes, 299
    - thrombophilic, 300
  - magnetic resonance angiography, 87–88
  - subacute, 305
  - treatment, 325–333
  - venous anatomy, 296–297
- Mesenteric vessels anatomy, 211, 212
- Microscopic polyangiitis (MP), 133
- Mother-and-child technique.
- See* Double-coaxial technique
- MRA. *See* Magnetic resonance angiography (MRA)
- Multidetector computed tomography (MDCT), 80
- Myeloproliferative neoplasms, 313
- N**
- Nathanson liver retractor, 372
  - Nationwide Inpatient Sample (NIS)
    - mortality rates, 267, 268
    - procedures volume, 266

- Neurofibromatosis type I (NF-I), 140–143
- Non-atherosclerotic causes, mesenteric arterial disease
- differential diagnosis, 135–138
  - gastrointestinal (GI) involvement, vasculitis
    - anatomic considerations, 124
    - angiography, 130
    - clinical features, 125–128
    - computed tomography, 129–130
    - duplex ultrasound, 129
    - endoscopy and colonoscopy, 129
  - mesenteric vasculitis, specific disorders
    - Behçet syndrome, 134–135
    - giant cell arteritis, 131
    - Henoch–Schönlein syndrome, 133
    - microscopic polyangiitis, 133
    - polyarteritis nodosa, 131–132
    - rheumatoid vasculitis, 134
    - systemic lupus erythematosus, 134
    - Takayasu’s arteritis, 131
    - thromboangiitis obliterans, 135
    - Wegener granulomatosis, 133
  - neurofibromatosis, 140–143
  - treatment
    - endovascular treatment, 140
    - medical, 138
    - surgical approach, 139
- Non-invasive arterial imaging
- computed tomography
    - MDCT, 80
    - rationale, 79–80
  - computed tomography angiography
    - clinical role and imaging considerations, 80–81
    - limitations, 90–91
  - magnetic resonance angiography
    - acute mesenteric ischemia, 85–87
    - chronic mesenteric ischemia, 82–85
    - limitations, 91
    - median arcuate ligament syndrome, 89
    - mesenteric venous thrombosis, 87–88
    - non-occlusive mesenteric ischemia, 88
    - rationale, 79–80
- Non-occlusive mesenteric ischemia (NOMI)
- AMI management by etiology, 205–206
  - angiography, 339
  - clinical presentation, 338
  - diagnostic considerations, 338
  - etiology, 337–338
  - laboratory assays, 339
  - magnetic resonance angiography, 88
  - MRI, 340
  - treatment
    - goal, 344
    - intra-arterial application, 345–346
    - key steps, 344
    - mortality, 343
    - pharmacological, 344–345
    - surgical, 345
- O**
- Octreotide, 286–287
- Open and endovascular revascularization
- contemporary results, 271, 272
  - vs. laparotomy and bowel resection rates, 269, 270
  - long-term survival, 273–274
  - Mayo Clinic experience, 268–271
  - morbidity and mortality, 269, 270
  - newer technique results, 273
  - NIS, 266–268
  - population-based registry results, 271, 272
- Open and hybrid mesenteric revascularization, AMI
- bowel viability, 236–237
  - complications, 237
  - considerations
    - SMA exposure, 227–228
    - superior mesenteric artery bypass, 229–232
    - supraceliac aorta, exposure and control, 228
    - thromboendarterectomy, 228–229
  - diagnosis, 225–226
  - initial treatment and resuscitation, 226
  - outcomes, 237
  - postoperative care, 237
  - ROMS, 232–235
- Open mesenteric catheter embolectomy.
- See* Mesenteric embolism
- Open mesenteric reconstructions
- patient outcome, 158–160
  - patient survival, 161–162
  - recurrent symptoms, 159, 161
  - redo open reconstruction, 161
  - re-intervention, 159, 161
  - surgical treatment
    - exposure, 145–149
    - technique, 150–155
    - symptom relief, 159, 161
- Open surgical techniques
- vs. endovascular therapy, 453–454
  - revascularizations
    - CAD/ HAD, 410

Open surgical techniques (*cont.*)

IVAD, 408–409

RAD, 410

SMAD, 410

SIVAD repair, 422–424

visceral artery aneurysms, 443, 451–452

Opioids, 286

Oral rehydration solution (ORS)

commercial, 283

modified WHO recipe, 283, 284

Orbital atherectomy, 177–179

**P**

Pancreaticoduodenal artery

aneurysms (PDAAs)

clinical presentation, 434–435

epidemiology and etiology, 438

issues, 450

rupture rate, 439

Pars flaccida approach. *See* Antegastric

approach

PDAAs. *See* Pancreaticoduodenal artery

aneurysms (PDAAs)

Percutaneous angioplasty and stenting

(PTA/S), 269

Peripherally inserted central catheter

(PICC), 284

Peripheral venous thrombosis, 329

Planned, repeat laparotomy.

*See* Second-look laparotomy

Polyarteritis nodosa (PAN), 131–132

Portal vein thrombosis, 314–315

Postprandial mesenteric

hyperemia, 27–28

Prostaglandin E1 (PGE1), 344, 345

Prothrombin G20210A mutation, 317

Pulseless disease. *See* Takayasu's arteritis**R**

Renal artery dissection (RAD)

clinical presentations, 390–391

open repair, 410

Retrogastric approach, 364–365

Retrograde hybrid revascularization, 179–181

Retrograde open mesenteric stenting

(ROMS), 232–235

Rheumatoid vasculitis (RV), 134

Right crus approach, 365–366

Robotic-assisted laparoscopic

approach, 369–370,

377–379

**S**

Second-look laparotomy

abdominal wall closure, temporary

and permanent, 258–261

rationale, 254–255

technique, 256–258

timing, 255–256

Secretin, 278

Selective arteriography, VAA, 441

Selective visceral artery angiography, 96, 98

Sepsis, 288

Short bowel syndrome (SBS)

clinical phase, 280

definition, 277–278

intestinal adaptation, 279–280

management

intestinal transplantation/SBT, 288

nutritional strategy, 281–284

pharmacologic treatments, 284–288

signs and symptoms, 278

types, 278–280

Single-nucleotide polymorphisms, 74

Sinus-SuperFlex nitinol stent, 412

SISMAD. *See* Spontaneous isolated SMA

dissection (SISMAD)

SIVAD. *See* Spontaneous isolated visceral

artery dissection (SIVAD)

SMA. *See* Superior mesenteric artery (SMA)SMAAs. *See* Superior mesenteric artery

aneurysms (SMAAs)

Small bowel transplantation (SBT), 288

Splanchnic venous thrombosis

acquired risk factors

acute pancreatitis, 313

characteristics and etiology, 311, 312

clinical manifestation, 313

essential thrombocythemia, 313

laboratory assessment, 311

prominent cause, 314

hepatic veins drain, 309

incidence, 310

management, 320–321

thrombophilia testing

clinical entity, 317

conventional panel, 316

heparin therapy, 316

hormonal therapy, 317

indiscriminate, 315

inherited characteristics, 317, 318

prevalence, 317, 319

risk factor, 316

thrombotic process, 309–310

Splenectomy, 446–447



- Splenic artery aneurysms (SAAs)  
 clinical presentation, 432  
 epidemiology and etiology, 436–437  
 issues, 446–448  
 rupture rate, 439
- Splenic atrophy, 452
- Splenic vein thrombosis, 331, 332
- Splenopancreatectomy, 447
- Spontaneous isolated SMA dissection (SISMAD)  
 endovascular intervention, 424–426  
 medical management, 421  
 open surgical repair, 424
- Spontaneous isolated visceral artery dissection (SIVAD)  
 celiac artery dissection, 422  
 endovascular repair, 422, 424–426  
 medical management, 419–422  
 open surgical repair, 422–424  
 treatment algorithm, 420
- Stent-graft technique, 445, 448
- Stenting  
 bifurcated, 179  
 endovascular repair, 425  
 visceral arteries, 412–413
- Subacute mesenteric vein thrombosis  
 clinical presentation, 301, 302  
 diagnosis, 305  
 treatment, 330–331
- Superior mesenteric artery (SMA), 431  
 anatomy  
 normal, 14–15  
 variant, 21–22  
 vascular, 26  
 bypass, 229–230  
 antegrade mesenteric, 230  
 retrograde type, 231–232  
 endovascular group, 268  
 exposure, 227–228  
 occlusion, thrombolysis, 273  
 reimplantation, 235–236
- Superior mesenteric artery aneurysms (SMAAs)  
 clinical presentation, 433–434  
 epidemiology and etiology, 437  
 issues, 449  
 rupture rate, 439
- Superior mesenteric artery dissection (SMAD)  
 and aneurysmal dilatation, 395  
 classification, 397–398  
 clinical presentations, 388–389  
 endovascular repair, 412, 413  
 etiology, 391–392  
 open surgical repair, 408, 409  
 surgical revascularization procedures, 410
- Superior mesenteric venous, 333
- Systemic lupus erythematosus (SLE), 134
- T**
- Takayasu's arteritis, 109, 131
- Teduglutide, 287–288
- Thromboangiitis obliterans (TAO), 109, 135
- Thrombolysis  
 catheter-directed, 101  
 SMA occlusion, 273
- Thrombophilia  
 clinical entity, 317  
 conventional panel, 316  
 heparin therapy, 316  
 hormonal therapy, 317  
 indiscriminate, 315  
 inherited characteristics, 317, 318  
 prevalence, 317, 319  
 risk factor, 316  
 strong, 317
- Thrombosis, larger veins, 333
- Tonometry, 118. *See also* Gastric tonometry
- Total parenteral nutrition (TPN), 283, 284
- Transaortic visceral artery endarterectomy, 149
- Transcatheter embolization, 444–445
- Trocars, laparoscopic, 371
- U**
- Ulcer-like projection (ULP), 397
- Ultrasonic dissector, laparoscopic  
 transperitoneal approach, 371
- V**
- VAAs. *See* Visceral artery aneurysms (VAAs)
- Vasculitis. *See also* Non-atherosclerotic  
 causes, mesenteric arterial disease  
 classification, 124–125  
 gastrointestinal (GI) manifestations, 123
- Visceral artery aneurysms (VAAs), 431  
 clinical presentation, 432–435  
 clinical presentations, 432  
 diagnostic considerations, 440–441  
 endovascular techniques, 443–446  
 epidemiology and etiology, 435–439  
 indications for interventions, 442–443  
 laboratory studies, 441  
 observation, 442  
 open surgical techniques, 443  
 rupture rate, 439

Visceral pseudoaneurysms, 436  
Visible light spectroscopy (VLS)  
  after intervention, 69  
  diagnostic value, 69  
  limitations, 70–71  
  optimization, 72–73  
  postprandial measurements, 73  
  procedure, 68–69  
  sensitivity and specificity, 69  
  sublingual measurements, 72–73  
  vs. tonometry, 69–70  
  use, 67–68

von Recklinghausen disease.  
  *See* Neurofibromatosis  
  type I (NF-I)

**W**

WALLSTENT, 412  
Wegener granulomatosis (WG), 133

**Z**

Zilver 635®, 412